Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

The JAK2V617F mutation may be present several years before the occurrence of overt myeloproliferative disorders

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Campbell PJ, Green AR . The myeloproliferative disorders. New Engl J Med 2006; 355: 2452–2466.

    Article  CAS  Google Scholar 

  2. Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006; 108: 346–352.

    Article  CAS  Google Scholar 

  3. Sidon P, El Housni H, Dessars B, Heimann P . The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 2006; 20: 1622.

    Article  CAS  Google Scholar 

  4. McClure R, Mai M, Lasho T . Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 2006; 20: 168–171.

    Article  CAS  Google Scholar 

  5. Passamonti F, Rumi E, Pietra D, Lazzarino M, Cazzola M . JAK2 (V617F) mutation in healthy individuals. Br J Haematol 2007; 136: 678–679.

    Article  Google Scholar 

  6. Xu X, Zhang Q, Luo J, Xing S, Li Q, Krantz SB et al. JAK2(V617F): prevalence in a large Chinese hospital population. Blood 2007; 109: 339–342.

    Article  CAS  Google Scholar 

  7. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P . Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86: 3118–3122.

    CAS  Google Scholar 

  8. Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV . The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 1998; 92: 3362–3367.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Corresponding author

Correspondence to C Bellanné-Chantelot.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bellanné-Chantelot, C., Jego, P., Lionne-Huyghe, P. et al. The JAK2V617F mutation may be present several years before the occurrence of overt myeloproliferative disorders. Leukemia 22, 450–451 (2008). https://doi.org/10.1038/sj.leu.2404896

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404896

This article is cited by

Search

Quick links